https://www.selleckchem.com/
High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10-24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported. In this study, we evaluated the differences in efficacy and safety between two different IVIG administration speeds. This was a multicenter, unblinded, randomized controlled study. Patients newly diagnosed with KD were randomized into two groups one who received IVIG over 12 h (12H